NCT07033689View on ClinicalTrials.gov

Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II)

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

March 1, 2027

Conditions
Pancreatic Cancer
Interventions
DEVICE

Suizenji (an ultrasound-guided HIFU therapy system)

Suizenji (an ultrasound-guided HIFU therapy system)

DRUG

Nal-IRI/FL

Standard of care

DRUG

mFOLFIRINOX adjuvant chemotherapy

standard of care

DRUG

Gem/nab-PTX

standard of care

Trial Locations (1)

94305

Stanford University, San Francisco

All Listed Sponsors
lead

SONIRE Therapeutics Inc.

INDUSTRY

NCT07033689 - Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) | Biotech Hunter | Biotech Hunter